Oxidative stress and antioxidants in interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 5, 2010, Pages 516-520

  Bast, Aalt ^a   Weseler, Antje R ^a   Haenen, Guido R M M ^a   Den Hartog, Gertjan J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

antioxidants; interstitial lung disease; N acetylcysteine; oxidative stress

Indexed keywords

ACETYLCYSTEINE; AMIODARONE; ANTIOXIDANT; AZATHIOPRINE; BLEOMYCIN; NITROFURANTOIN; OXYGEN; OXYGEN RADICAL; PIRFENIDONE; PREDNISONE; REACTIVE OXYGEN METABOLITE;

ASBESTOSIS; CLINICAL TRIAL; DIET THERAPY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG SARCOIDOSIS; LUNG TOXICITY; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; REDOX STRESS; REVIEW; SILICOSIS; TISSUE INJURY; TREATMENT OUTCOME;

ACETYLCYSTEINE; ANTIOXIDANTS; HUMANS; LUNG DISEASES, INTERSTITIAL; OXIDATIVE STRESS; PYRIDONES; REACTIVE OXYGEN SPECIES;

EID: 77955279916     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833c645d     Document Type: Review

References (31)

1. Ichinose M, Sugiura H, Yamagata S, et al. Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. Eur Respir J 2003; 22:457-461; Erratum in: Eur Respir J 2004; 23:496.
2. Hamelin BA, Xu K, Vallé F, et al. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994; 56:521-529.
3. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblasts activation and fibrogenic responses to lung injury. Nat Med 2009; 15:1077-1081.
4. Guzlik TJ, Harrison GG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006; 11-12:524-533.
5. Dammanahalli KJ, Sun Z. Endothelins and NADPH oxidases in the cardiovascular system. Clin Exp Pharmacol Physiol 2008; 35:2-6.
6. Boots AW, Hristova M, Kasahara DI, et al. ATP-mediated activation of the NADPH oxidase DUOX1 mediates airway epithelial responses to bacterial stimuli. J Biol Chem 2009; 284:17858-17867.
7. Psathakis K, Mermigkis D, Papatheodorou G, et al. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest 2006; 36:362-367.
8. Rosias RP, den Hartog GJ, Robroeks CM, et al. Free radicals in exhaled breath condensate in cystic fibrosis and healthy subjects. Free Radic Res 2006; 40:901-909.
9. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of highdose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156:1897-1901.
10. Boots AW, Drent M, Swennen ELR, et al. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir Med 2009; 103:364-372.
11. Bellocq A, Azoulay E, Marullo S, et al. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999; 21:128-136.
12. Crimi E, Sica V, Williams-Ignarro S, et al. The role of oxidative stress in adult critical care. Free Radic Biol Med 2006; 40:398-406.
13. Wijnen PAHM, Drent M, Nelemans PJ, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary toxicity. A case-control study in the Netherlands. Drug Saf 2008; 31:1125-1134.
14. Wijnen PA, Linssen CF, Haenen GR, et al. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 2010; 14:23-30.
15. Cho HY, Reddy SP, Yamamoto M, Kleeberger SR. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004; 18:1258-1260.
16. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1804-1808.
17. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103:927-931.
18. Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and alpha-tocopherol, an antioxidant vitamin, on experimental reflux oesophagitis in rats. Eur J Pharmacol 2008; 589:233-238.
19. Du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Disc 2010; 9:129-140.
20. Behr J, Demedts M, Buhl R, et al., IFIGENIA study group. Lung function in idiopathic pulmonary fibrosis: extended analyses of the IFIGENIA trial. Respir Res 2009; 10:101.
21. Bast A, Haenen GRMM. α-Lipoic acid and N-acetylcysteine: new concepts for old drugs. In: Cadenas E, Packer L, editors. Biothiols in health and disease. New York: Marcel Dekker; 1995. pp. 409-425.
22. Demedts M, Behr J, Buhl R, et al., IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
23. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.
24. Anonymous. First drug for idiopathic pulmonary fibrosis approved in Japan. Nat Rev Drug Disc 2008, 7:966-967.
25. Salazar-Montes A, Ruiz-Corro L, Ló pez-Reyes A, et al. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008; 595:69-77.
26. Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun 2008; 372:19-23.
27. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of Nacetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6:593-597.
28. Qi S, den Hartog GJ, Bast A. Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels. Toxicol Appl Pharmacol 2009; 237:111-118.
29. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Disc 2009; 8:153-171.
30. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172:417-422.
31. Boots AW, Haenen GRMM, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008; 585:325-337.